Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Sep 23, 2022--
The "Global Nephrotic Syndrome Diagnostics & Therapeutics Market Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
The global nephrotic syndrome diagnostics & therapeutics market is anticipated to grow at a CAGR of 5.6% during the forecast period. Nephrotic syndrome is a kidney disease in which the body excretes an excessive amount of protein in the urine. Damage to the clusters of tiny blood vessels in kidneys that remove waste and excess water from blood is the most common cause of the nephrotic syndrome.
Diabetes, which can cause diabetic nephropathy and thus affect glomeruli, has been one of the major factors driving the market growth during the forecast period. The other factors being the increasing rate of hyperlipidemia, the rise of complications, such as thromboembolism, HIV, hepatitis B, and hepatitis C, also contribute to the rising rate of nephrotic syndrome incidence and prevalence across the globe will further driving the growth of the market.
Several factors, such as the absence of reimbursement policies in both low- and middle-income countries, serve as a significant restraint on the demand for nephrotic syndrome diagnostics and therapeutics. The high cost of a kidney transplant and dialysis treatment also has an impact on market growth. Moreover, pipeline drugs for nephrotic syndrome would drive the demand creating opportunities for the growth of the market.
The Report Covers
Key Topics Covered:
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
5.1. Global Nephrotic Syndrome Diagnostics & Therapeutics market By Diagnosis Tests
5.1.1. Urinalysis
5.1.2. Blood Tests
5.1.3. Kidney Biopsy
5.1.4. Others (CT Scan, Renal Ultra-Sonography)
5.2. Global Nephrotic Syndrome Diagnostics & Therapeutics market by Treatment
5.2.1. Blood Pressure Lowering Medications
5.2.1.1. Angiotensin-Converting Enzyme (ACE) Inhibitors
5.2.1.2. Angiotensin Receptor Blockers (ARBs)
5.2.1.3. Others (Renin Inhibitors and Benazepril)
5.2.2. Immune System-Suppressing Medications
5.2.3. Cholesterol-Reducing Medications
5.2.4. Others (Blood Thinners)
6. Regional Analysis
7. Company Profiles
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/yrc7b
View source version on businesswire.com:https://www.businesswire.com/news/home/20220923005248/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH MEDICAL DEVICES
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 09/23/2022 07:09 AM/DISC: 09/23/2022 07:09 AM
http://www.businesswire.com/news/home/20220923005248/en